A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Condition:   Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Intervention:   Biological: Efgartigimod PH20 SC Sponsor:   argenx BVBA Not yet recruiting

Source: ClinicalTrials.gov - February 21, 2020 Category: Research Source Type: clinical trials